HK Stock Market Move | CENTRALCHINA MT (09982) resumed trading after a suspension of more than 20 months, with a surge of nearly 64% in the morning session.
China Yuangeng (09982) suspended trading on April 2, 2024, and resumed trading after more than 20 months, with a sharp rise of nearly 64% this morning.
CENTRALCHINA MT (09982) suspended trading on April 2, 2024, and resumed trading after more than 20 months. This morning, the stock surged nearly 64%, and as of the time of writing, it was up 38.18% at HK$0.152, with a turnover of HK$24.9265 million.
On the news front, on the evening of December 19, CENTRALCHINA MT announced that it had fulfilled the resumption guidance, including publishing all as-yet-unpublished financial performance and resolving any audit revisions. To date, the group has fully repaid the principal amounts of ten loans totaling RMB 750 million provided to several real estate companies, with outstanding accrued interest of RMB 53 million. The company has instructed legal advisors to review and recover the outstanding amounts.
Related Articles

SIMCERE PHARMA (02096) subsidiary has signed an exclusive licensing agreement with Ipsen for SIM0613 (LRRC15 antibody-conjugated drug).

UNISOUND (09678) releases the large model "Shanhai Zhiyi Big Model 5.0" in the medical field.

HK Stock Market Move | CCIAM FUTURE EN(00145) fell sharply by 62%, giving back most of the gains in the month. Issuing additional shares based on a "2 shares for 1" benchmark.
SIMCERE PHARMA (02096) subsidiary has signed an exclusive licensing agreement with Ipsen for SIM0613 (LRRC15 antibody-conjugated drug).

UNISOUND (09678) releases the large model "Shanhai Zhiyi Big Model 5.0" in the medical field.

HK Stock Market Move | CCIAM FUTURE EN(00145) fell sharply by 62%, giving back most of the gains in the month. Issuing additional shares based on a "2 shares for 1" benchmark.






